Ultragenyx Pharmaceutical (RARE) Operating Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Operating Expenses for 14 consecutive years, with $305.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 8.16% year-over-year to $305.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 11.5% YoY), while the FY2025 annual figure was $1.2 billion, up 10.22% from the prior year.
• Operating Expenses slipped to $305.0 million in Q1 2026 per RARE's latest filing, from $320.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $330.8 million in Q3 2025 and bottomed at $216.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $272.0 million across 5 years, with a median of $271.5 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 84.15% — and 2023, when it retreated 23.0%.
• Ultragenyx Pharmaceutical's Operating Expenses stood at $249.0 million in 2022, then gained by 0.0% to $249.0 million in 2023, then rose by 15.25% to $287.0 million in 2024, then grew by 11.71% to $320.6 million in 2025, then declined by 4.85% to $305.0 million in 2026.
• Business Quant data shows RARE's Operating Expenses at $305.0 million in Q1 2026, $320.6 million in Q4 2025, and $330.8 million in Q3 2025.